Novo Nordisk sues Eli Lilly over ads as GLP-1 market hits ‘inflection point’
The Danish company Novo says U.S.-based Lilly isn’t including the most up-to-date clinical information about its drugs. O recorte ajuda a contextualizar a pauta dentro de Carreira.